Jeroen de Vrij
CEO, ExoVectory
Jeroen de Vrij is listed as CEO, ExoVectory. Jeroen is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Jeroen. Is this you? Claim this profile.
About
Jeroen de Vrij is founder and CEO of ExoVectory and Group Leader Gene Therapy at the Erasmus MC Cancer Institute in the Netherlands. Trained as a gene therapy researcher, he obtained his PhD at Leiden University Medical Center, where he worked on virus-based gene therapy approaches for cancer treatment. Over the past decade, his research has focused on exploring extracellular vesicles (EVs) and Virus Like Particles (VLPs) as tool for delivery of cell and gene therapies. At ExoVectory, this technology is further developed and commercialized as next-generation delivery platform.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel discussion Speaker · 19 January 2027
- Session 2: Non-viral delivery Part 1 - R&D and Regulatory focus Speaker · 19 January 2027
- Panel discussion Speaker · 21 January 2027
- Session 9: Next-generation vector systems and emerging payloads – how and where can they enable the cell & gene therapy field to advance? Speaker · 21 January 2027
Spoke alongside
People who have shared a session with Jeroen at events on B2DB.
- J. Rodrigo Mora CSO · BreezeBio 2 shared sessions
- Liangfang Zhang Joan and Irwin Jacobs Chancellor Professor & Chair, Aiiso Family Department of Chemical and Nano Engineering, Jacobs School of Engineering · University of California San Diego 2 shared sessions
- Mercedes Segura Gally VP Process Development · Editas Medicine 2 shared sessions
- Nathalie Clément Senior Vice President, Vector Development · Siren Biotechnology 2 shared sessions
- Sheena Smith Assistant Professor of Biotechnology, School of Chemistry, Chemical Engineering and Biotechnology (CCEB) · Nanyang Technological University, Singapore 1 shared session